VacZine Analytics  
MarketVIEW: Novel coronavirus [COVID-19] vaccines

Published: May 2020

The novel coronavirus, SARS-CoV-2 emerged from Wuhan City, Hubei Province of China in late December 2019, causing a cluster of atypical pneumonia cases among stallholders at a seafood wholesale market. The resulting respiratory disease, later referred to as COVID-2019, was designated by the World Health Organisation (WHO) a Public Health Emergency of International Concern (PHEIC) on the 30th January 2020 and later a global pandemic by March 11th, 2020.

COVID-19 has affected ~215 countries/territories with greater than 5.8 million confirmed cases and over 360 thousand deaths (as of 29th May 2020), mainly in the elderly and those with chronic underlying conditions. It is predicted that a large proportion of the global population will be infected with SARS-CoV-2 causing further excess morbidity, mortality and substantial economic loss. SARS-CoV-2 is related to other coronaviruses such as MERS-CoV (2012), SARS-CoV-1 (2003) and the endemic human betacoronaviruses OC43 and HKU1 which cause the common cold.

There is no specific treatment for COVID-19 nor widespread immunity. Numerous efforts are now underway to develop new prophylatic vaccines and antiviral therapeutics to address the emergence of SARS-CoV-2. For vaccines, the Coalition of Epidemic Preparedness Innovations (CEPI) is helping fund candidates including the frontrunners being developed by Moderna Therapeutics, Pfizer (BioNTech), Inovio Pharmaceuticals, and University of Oxford/AZ which have recently entered Phase I or Phase I/II clinical testing. Other clinical stage vaccine programs are underway in China e.g. Sinovac Antivirals e.g. remdesivir and other agents are beginning to make headway although, for some, the scientific validity is being questioned due to a lack of well controlled studies.

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>250 slides) and 2 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic novel coronavirus vaccine to 2045. The model has three detailed and fully adjustable deployment scenarios which include the major Western economies, emerging economies of SE Asia, LATAM and the Far East*. 'At risk' populations or identified target segments (based on latest understanding) are included. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided along with a discussion of hypothetical vaccine target product profiles (TPPs). *Some are rolled up, other scenarios are global - all countries

THIS PRODUCT IS A SUMMARY PRESENTATION (>250 slides, .pdf form) + 2 x FORECAST MODEL(s) (.xls)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV086 Click here>> CONTACT US
*This is a licensed product. Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase. Picture Credit: CDC (Unsplash)

Return to main list>> Questions about this report?






© 2020 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains